Anti-PD-L1 Antibody Dosing Schedules for Maintenance Convenience
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing schedules for atezolizumab, a PD-L1 antibody, lack flexibility and may not provide optimal convenience for patients, particularly in maintenance phase therapies.
Innovation Solution
Alternative dosing schedules of atezolizumab at 1680 mg every 4 weeks or 840 mg every 2 weeks are proposed, maintaining similar efficacy and safety as the standard 1200 mg every 3 weeks regimen, allowing greater flexibility and patient convenience.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the standard dosing schedule of 1200 mg every 3 weeks is used, then efficacy and safety are maintained, but patient convenience and flexibility are reduced
Solution Approach 1:
The patent applies parameter changes by modifying the dosing interval from every 3 weeks to every 4 weeks, and adjusting the dose amount from 1200 mg to 1680 mg. This changes the dosing parameters while maintaining the therapeutic effect, thereby improving patient convenience without compromising efficacy and safety.
2Adaptability or versatility
If alternative dosing schedules are implemented, then patient convenience is improved, but dosing flexibility is limited
Solution Approach 1:
The patent applies dynamics by providing multiple dosing schedule options (every 2 weeks at 840 mg, every 3 weeks at 1200 mg, and every 4 weeks at 1680 mg) that can be dynamically selected based on patient needs and treatment phase, thereby enhancing dosing flexibility and adaptability.
3Ease of operation
If dosing intervals are extended, then patient convenience is enhanced, but treatment frequency is reduced
Solution Approach 1:
The patent applies periodic action by establishing fixed dosing intervals (every 2, 3, or 4 weeks) with corresponding dose amounts, creating a regular treatment rhythm that improves patient convenience while maintaining adequate treatment frequency through appropriate dose selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The alternative dosing schedules provide similar efficacy and safety to the standard regimen while enhancing patient convenience, particularly in maintenance therapies.
Implementation Method 1
Atezolizumab targets human programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) and tumor cells, and inhibits its interaction with its receptors programmed death-1 (PD-1) and B7.1
Data Source
AI summary
The present disclosure relates to methods, uses, and kits related to treating cancers by administering an anti-PD-L1 antibody (e.g., atezolizumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered in 840 mg every 2 weeks or 1680 mg every 4 weeks for two or more cycles.